Home・Elenco Azioni・CRISPR Therapeutics AG

CRISPR Therapeutics AG

Chiusa

SettoreSettore sanitario

58.71 4.21

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

55.99

Massimo

56.94

Metriche Chiave
By Trading Economics
Entrata	-91M -214M
Vendite	8.7M 10M
EPS	-0.94
Margine di Profitto	-2,102.79
Dipendenti	393
EBITDA	7.3M -110M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+30.1% upside

Dividendi
By Acuity
Utili prossimi	9 nov 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	519M 5.1B
Apertura precedente	54.5
Chiusura precedente	58.71

Notizie sul Sentiment di mercato

By Acuity

26%

74%

28 / 339 Classifica in Healthcare

CRISPR Therapeutics AG Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

19 set 2026, 00:02 UTC

Correlated Moves

CRISPR Therapeutics AG is advancing in after-market trading, likely in sympathy with Editas Medicine Inc, amid broader economic concerns.

18 set 2026, 23:01 UTC

CRISPR Therapeutics AG is advancing in after-market trading, moving higher alongside the broader market, following a peak return earlier in the session.

17 set 2026, 23:51 UTC

CRISPR Therapeutics AG declined modestly during after-market hours on Thursday, breaking a recent trend of higher daily closes.

16 set 2026, 23:16 UTC

CRISPR Therapeutics AG is declining in after-market hours, trading near the lower end of its one-month range and below its 20-day moving average.

15 set 2026, 23:01 UTC

CRISPR Therapeutics AG shares are higher in after-market hours, reflecting overall market momentum despite a decline in the New York Empire State Manufacturing Index.

14 set 2026, 23:01 UTC

CRISPR Therapeutics AG shares are higher in after-market trading, reflecting a strong performance despite declining major indices and rising crude oil prices.

11 set 2026, 23:01 UTC

CRISPR Therapeutics AG shares are higher in after-market trading, influenced by a narrower-than-expected U.S. budget deficit of $167 billion for August.

10 set 2026, 20:07 UTC

CRISPR Therapeutics AG shares are lower amid a broader market decline following the European Central Bank's interest rate hike and rising Treasury yields.

8 set 2026, 20:07 UTC

CRISPR Therapeutics AG shares are lower today, marking four consecutive sessions of declines amid market speculation on potential interest rate hikes.

4 set 2026, 23:37 UTC

Correlated Moves

CRISPR Therapeutics AG shares rose in after-market trading, reflecting a modest increase since Friday's close, aligning with Beam Therapeutics' sector performance.

3 set 2026, 23:56 UTC

CRISPR Therapeutics AG shares are lower in after-hours trading, continuing a decline since Thursday's close, despite broader market gains. No specific news was identified.

2 set 2026, 19:46 UTC

CRISPR Therapeutics AG shares are lower today, continuing a four-day decline amid rising U.S. Treasury yields and inflationary pressures affecting the biotechnology sector.

1 set 2026, 23:06 UTC

CRISPR Therapeutics AG shares are lower in after-market trading, with no specific news identified to explain the movement. The stock has declined in three consecutive sessions.

31 ago 2026, 23:06 UTC

CRISPR Therapeutics AG shares are higher in after-market trading, reflecting stable performance amid broader economic sentiment and expectations for a potential rate hike.

29 ago 2026, 00:02 UTC

CRISPR Therapeutics AG shares are lower in after-market hours, continuing a trend of notable weakness amid rising market expectations for an interest rate hike.

28 ago 2026, 22:51 UTC

CRISPR Therapeutics AG shares are lower in after-market hours, continuing a trend of weakness since Friday's close with no specific news identified.

27 ago 2026, 23:02 UTC

CRISPR Therapeutics AG shares are higher in after-market trading, reflecting overall strength despite a slight pullback from earlier highs. No specific news was identified.

26 ago 2026, 23:02 UTC

CRISPR Therapeutics AG shares are higher in after-market hours, maintaining strength above the 20-day moving average and near the upper end of their one-month range.

25 ago 2026, 23:06 UTC

CRISPR Therapeutics AG shares are lower in after-market hours, reflecting a decline after Tuesday's close, despite a significant gain over the past month.

24 ago 2026, 23:01 UTC

Shares of CRISPR Therapeutics AG declined in after-market trading, despite briefly recovering earlier in the session. The stock remains above its 20-day moving average.

21 ago 2026, 23:36 UTC

CRISPR Therapeutics AG shares are higher in after-market trading, maintaining a position above the 20-day moving average and near the one-month range's upper end.

20 ago 2026, 19:51 UTC

Correlated Moves

Shares lower today amid broader market pressures; SPDR S&P Biotech declines.

19 ago 2026, 23:01 UTC

CRISPR Therapeutics AG shares are lower in after-market trading, continuing a decline since Wednesday's close amid notable volatility.

18 ago 2026, 22:16 UTC

CRISPR Therapeutics AG shares are lower in after-market trading, reflecting unusual downward momentum amid broader market declines in major U.S. tech stocks.

17 ago 2026, 23:06 UTC

Correlated Moves

CRISPR Therapeutics AG shares are lower in after-market trading, reflecting broader market sentiment affecting small-cap stocks amid a slight decline in the Russell 2000 Index.

14 ago 2026, 19:16 UTC

CRISPR Therapeutics AG shares are lower today amid broader investor caution following a decline in U.S. retail sales for July.

13 ago 2026, 23:46 UTC

Correlated Moves

CRISPR Therapeutics AG shares are higher in after-market trading, reflecting a positive trend in the biotechnology sector amid favorable economic conditions.

11 ago 2026, 19:21 UTC

CRISPR Therapeutics AG shares are trading higher amid rising oil prices and inflation concerns ahead of upcoming U.S. inflation data. No specific news was identified.

10 ago 2026, 23:06 UTC

No specific news was identified for CRISPR Therapeutics AG, which traded roughly flat during after-market hours, remaining near the upper end of its one-month range.

7 ago 2026, 20:06 UTC

News

Correlated Moves

Social Media

CRISPR Therapeutics AG is gaining amid positive social media sentiment and bullish chart patterns, aligning with the upward trend in the ARK Genomic Revolution ETF.

Confronto tra pari

Modifica del prezzo

CRISPR Therapeutics AG Previsione

Obiettivo di Prezzo

By TipRanks

30.1% in crescita

Previsioni per 12 mesi

Media 73.583 USD 30.1%

Alto 110 USD

Basso 45 USD

Basato su 13 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per CRISPR Therapeutics AG - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

13 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 13 che hanno fornito valutazioni azionarie a CRISPR Therapeutics AG - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

28 / 339 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.